Bank of Montreal Can Has $7.86 Million Stock Holdings in Align Technology, Inc. $ALGN

Bank of Montreal Can decreased its position in shares of Align Technology, Inc. (NASDAQ:ALGN) by 34.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 41,489 shares of the medical equipment provider’s stock after selling 21,931 shares during the quarter. Bank of Montreal Can owned about 0.06% of Align Technology worth $7,855,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. iA Global Asset Management Inc. bought a new position in shares of Align Technology during the second quarter worth $1,148,000. Tredje AP fonden raised its stake in Align Technology by 13.9% during the 2nd quarter. Tredje AP fonden now owns 131,232 shares of the medical equipment provider’s stock worth $24,846,000 after buying an additional 16,034 shares during the period. Cambiar Investors LLC acquired a new stake in Align Technology during the 2nd quarter worth $10,032,000. Plato Investment Management Ltd lifted its holdings in Align Technology by 88.0% during the second quarter. Plato Investment Management Ltd now owns 5,357 shares of the medical equipment provider’s stock worth $1,011,000 after acquiring an additional 2,507 shares in the last quarter. Finally, Geneva Capital Management LLC grew its stake in Align Technology by 5.6% in the second quarter. Geneva Capital Management LLC now owns 31,210 shares of the medical equipment provider’s stock valued at $5,909,000 after acquiring an additional 1,654 shares during the period. Institutional investors own 88.43% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on ALGN. Mizuho dropped their price target on Align Technology from $210.00 to $170.00 and set an “outperform” rating on the stock in a research report on Monday, October 13th. Leerink Partners raised their target price on shares of Align Technology from $172.00 to $189.00 in a report on Thursday, October 30th. Needham & Company LLC reaffirmed a “hold” rating on shares of Align Technology in a research note on Thursday, October 30th. Weiss Ratings cut shares of Align Technology from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, October 8th. Finally, UBS Group dropped their price objective on shares of Align Technology from $160.00 to $155.00 and set a “neutral” rating on the stock in a report on Thursday, October 16th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $175.45.

Align Technology Stock Up 0.8%

NASDAQ:ALGN opened at $134.84 on Monday. The company has a market cap of $9.67 billion, a P/E ratio of 26.13, a price-to-earnings-growth ratio of 1.49 and a beta of 1.84. Align Technology, Inc. has a twelve month low of $122.00 and a twelve month high of $246.19. The business has a 50 day moving average price of $132.60 and a two-hundred day moving average price of $160.44.

Align Technology (NASDAQ:ALGN) last announced its quarterly earnings data on Wednesday, October 29th. The medical equipment provider reported $2.61 EPS for the quarter, topping analysts’ consensus estimates of $2.38 by $0.23. Align Technology had a net margin of 9.50% and a return on equity of 14.06%. The business had revenue of $995.69 million for the quarter, compared to analyst estimates of $980.75 million. During the same quarter in the previous year, the firm posted $2.35 earnings per share. The firm’s revenue for the quarter was up 1.8% on a year-over-year basis. Align Technology has set its Q4 2025 guidance at EPS. As a group, analysts anticipate that Align Technology, Inc. will post 7.98 earnings per share for the current fiscal year.

Align Technology declared that its board has approved a share buyback program on Tuesday, August 5th that allows the company to buyback $200.00 million in shares. This buyback authorization allows the medical equipment provider to repurchase up to 2% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board of directors believes its stock is undervalued.

Align Technology Company Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.